Analysts Issue Forecasts for AURA Q3 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Aura Biosciences in a report released on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will earn ($0.47) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ FY2027 earnings at ($1.64) EPS.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09).

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Aura Biosciences presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Stock Down 0.8 %

NASDAQ AURA opened at $5.94 on Wednesday. The stock has a market capitalization of $296.71 million, a P/E ratio of -3.43 and a beta of 0.30. Aura Biosciences has a 52-week low of $5.77 and a 52-week high of $12.38. The firm has a 50-day moving average price of $7.57 and a 200 day moving average price of $8.62.

Insider Activity

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 23,045 shares of company stock worth $177,242. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Long Focus Capital Management LLC lifted its holdings in shares of Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after purchasing an additional 1,404,228 shares in the last quarter. Vanguard Group Inc. grew its holdings in Aura Biosciences by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock valued at $15,764,000 after buying an additional 112,296 shares during the last quarter. Franklin Resources Inc. increased its position in Aura Biosciences by 3.2% during the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company’s stock worth $14,164,000 after buying an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. raised its holdings in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after acquiring an additional 783,984 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after purchasing an additional 3,972 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.